Robert Ross, Surface Oncology CEO
Surface Oncology lays off 20% as biotech halts CD39 work on one of its ‘crown jewels’
Surface Oncology is letting go of 20% of its workforce as the biotech prunes its pipeline and narrows the scope of its lead drug. …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
